Dendritic cell paralysis
نویسندگان
چکیده
منابع مشابه
Dendritic cell paralysis
When airborne bacteria are inhaled into the lungs they are quickly taken up by resident dendritic cells (DCs), which ferry bacterial antigens to the lymph nodes. Once in the lymph node, DCs produce interleukin (IL)-12p70 to help activate bug-specific T helper (Th)-1 cells. According to Khader and colleagues on page 1805, DCs also use homodimers of the p40 subunit of IL-12p70 to help them embark...
متن کاملBlastic Plasmacytoid Dendritic Cell Neoplasm; A Report of Three Cases
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic myeloid malignancy that is known to be derived from plasmacytoid dendritic cells which are characterized by expression of CD4, CD56, and more specific markers such as CD123. Here, the authors present three cases of BPDCN diagnosed in the past two years and address different available diagnostic modalities such as morpho...
متن کاملDendritic Cell Maturation with CpG for Tumor Immunotherapy
Background: Bacterial DNA has immunostimulatory effects on different types of immune cells such as dendritic cells (DCs). Application of DCs as a cellular adjuvant represents a promising approach in the immunotherapy of infectious disease and cancers. Objectives: To investigate the effect of tumor antigen pulsed DCs in the presence of CpG-1826 in treatment of a murine model of cancer. Methods: ...
متن کاملComparison of Several Maturation Inducing Factors in Dendritic Cell Differentiation
Background: Dendritic cells (DCs) are professional antigen presenting cells that have an important role in the initiation of immune response. The use of maturation factors in dendritic cell differentiation provides a promising approach in immunotherapy. Objective: In this study, we compared tumor necrosis factor-α, polyribocytidylic acid, lipopolysacharide and CpG oligonucleotides in inducing d...
متن کاملDendritic Cell Immunotherapy, the Next Step in Cancer Treatment
Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Experimental Medicine
سال: 2006
ISSN: 1540-9538,0022-1007
DOI: 10.1084/jem.2037iti4